Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Yamanouchi Pharmaceutical Co and Fujisawa Pharmaceutical Co have now officially combined operations into a new corporation named Astellas Pharma Inc. The merged company ranks among the top 20 global pharmaceutical companies.
Subscribe to our email newsletter
Astellas’ focus will be on developing breakthrough products in the areas of immunology, infectious disease, dermatology, urology and cardiovascular disease, while continuing to explore unmet needs in other areas.
The company will continue to support its mainstay prescription products including Prograf, VESIcare, Protopic, Adenoscan, AmBisome and Flomax. In May, Mycamine will be the first product launched under the Astellas name, for the treatment of candida fungal infections.
The Astellas worldwide headquarters is located in Tokyo. In the US, Astellas will operate commercially under the name Astellas Pharma US, Inc, with headquarters located in Deerfield, Illinois, becoming a larger presence in the growing pharmaceutical industry in Illinois. Its European regional office is based in London, UK and additional Asian operations are located in China, Korea, Taiwan, Thailand, Philippines and Indonesia.